{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:16:50Z","timestamp":1773296210414,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejphar.2021.174484","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:32Z","timestamp":1631145632000},"page":"174484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension"],"prefix":"10.1016","volume":"916","author":[{"given":"Michel R.","family":"Corboz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-6411","authenticated-orcid":false,"given":"Adam J.","family":"Plaunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6496-2968","authenticated-orcid":false,"given":"Vladimir","family":"Malinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Gauani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-4721","authenticated-orcid":false,"given":"David","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter R.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174484_bib1","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174484_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/08958370802207318","article-title":"Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals","volume":"20","author":"Alexander","year":"2008","journal-title":"Inhal. Toxicol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174484_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120157","article-title":"Increased eicosanoid levels in the Sugen\/chronic hypoxia model of severe pulmonary hypertension","volume":"10","author":"Al-Husseini","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2021.174484_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ppul.24190","article-title":"Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension","volume":"54","author":"Bacha","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejphar.2021.174484_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2017.05.052","article-title":"RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats","volume":"810","author":"Bhat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174484_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pupt.2018.02.002","article-title":"Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil","volume":"49","author":"Chapman","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102002","article-title":"An overview of the biology of a long-acting inhaled treprostinil prodrug","volume":"65","author":"Chapman","year":"2020","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib8","first-page":"1","article-title":"Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil","volume":"7","author":"Chapman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2021.174484_bib9","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/bph.14472","article-title":"Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: hemodynamic benefits are not associated with improvements in arterial remodeling","volume":"175","author":"Chaudhary","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174484_bib10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.117.244798","article-title":"Impaired pulmonary arterial vasoconstriction and nitric oxide-mediated relaxation underlie severe pulmonary hypertension in the sugen-hypoxia rat model","volume":"364","author":"Christou","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib11","series-title":"Mol. Mech. Cong. Heart Dis. And Pulm. Hypert","first-page":"31","article-title":"Diverse pharmacology of prostacyclin mimetics: implications for pulmonary hypertension","author":"Clapp","year":"2020"},{"key":"10.1016\/j.ejphar.2021.174484_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.117.242099","article-title":"Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug","volume":"363","author":"Corboz","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2018.01.012","article-title":"Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats","volume":"49","author":"Corboz","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2020.106486","article-title":"Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in gene expression of human lung fibroblasts","volume":"152","author":"Corboz","year":"2021","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.ejphar.2021.174484_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","article-title":"Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2\u03b1 inhibitor","volume":"198","author":"Dai","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2021.174484_bib16","doi-asserted-by":"crossref","DOI":"10.1086\/675986","article-title":"Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series)","volume":"4","author":"De Raaf","year":"2014","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2021.174484_bib17","doi-asserted-by":"crossref","first-page":"L1164","DOI":"10.1152\/ajplung.00127.2015","article-title":"Serotonin transporter is not required for the development of severe pulmonary hypertension in the Sugen hypoxia rat model","volume":"309","author":"de Raaf","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib18","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s12350-016-0663-4","article-title":"Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416\/hypoxia rat model of severe pulmonary arterial hypertension","volume":"24","author":"Drozd","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2021.174484_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1242\/dmm.003616","article-title":"Idiopathic pulmonary arterial hypertension","volume":"3","author":"Firth","year":"2010","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.ejphar.2021.174484_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2021.174484_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/hrt.14.3.413","article-title":"Ventricular weight in cardiac hypertrophy","volume":"14","author":"Fulton","year":"1952","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2021.174484_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2021.174484_bib24","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1365-2559.1985.tb02811.x","article-title":"The assessment of cardiac hypertrophy at autopsy","volume":"9","author":"Hangartner","year":"1985","journal-title":"Histopathology"},{"key":"10.1016\/j.ejphar.2021.174484_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/753210","article-title":"Novel model of pulmonary artery banding leading to right heart failure in rats","author":"Hirata","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2021.174484_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1469-7580.2002.00096.x","article-title":"The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis","volume":"201","author":"Hopkins","year":"2002","journal-title":"J. Anat."},{"key":"10.1016\/j.ejphar.2021.174484_bib27","doi-asserted-by":"crossref","first-page":"L1042","DOI":"10.1152\/ajplung.90327.2008","article-title":"L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension","volume":"296","author":"Howell","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1165\/rcmb.2014-0488OC","article-title":"Marked strain-differences in the SU5416 rat model of severe pulmonary arterial hypertension","volume":"54","author":"Jiang","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2021.174484_bib29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"Kuwano","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174484_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and Su5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2021.174484_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-0044-100374","article-title":"Inhaled treprostinil-prodrug lipid nanoparticle formulations provide long-acting pulmonary vasodilation","volume":"68","author":"Leifer","year":"2018","journal-title":"Drug Res."},{"key":"10.1016\/j.ejphar.2021.174484_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.CIR.70.3.425","article-title":"Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window","volume":"70","author":"Lewis","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174484_bib34","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1038\/s41598-019-43225-3","article-title":"Pulmobinding imaging measures reduction of vascular adrenomedullin receptor activity with lack of effect of sildenafil in pulmonary hypertension","volume":"9","author":"Merabet","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174484_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019881954","article-title":"Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice","volume":"9","author":"Nikitopoulou","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2021.174484_bib36","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1100\/tsw.2007.184","article-title":"Prostanoid receptors in the human vascular wall","volume":"7","author":"Norel","year":"2007","journal-title":"ScientificWorldJ."},{"key":"10.1016\/j.ejphar.2021.174484_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.RES.0000261658.12024.18","article-title":"Rho Kinase\u2013mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats","volume":"100","author":"Oka","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174484_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19082372","article-title":"Prostanoid EP2 receptors are up-regulated in human pulmonary arterial hypertension: a key anti-proliferative target for treprostinil in smooth muscle cells","volume":"19","author":"Patel","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2021.174484_bib39","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1152\/japplphysiol.00083.2005","article-title":"Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation","volume":"99","author":"Sandifer","year":"2005","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1164\/rccm.200502-296OC","article-title":"Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension","volume":"172","author":"Schermuly","year":"2005","journal-title":"Am. J. Resp. Care Med."},{"key":"10.1016\/j.ejphar.2021.174484_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/2045-8932.83444","article-title":"Overview of current therapeutic approaches for pulmonary hypertension","volume":"1","author":"Stamm","year":"2011","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2021.174484_bib42","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cvr\/cvy004","article-title":"Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension","volume":"114","author":"Stenmark","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174484_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension","volume":"15","author":"Tarasevicience-Stewart","year":"2001","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2021.174484_bib45","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.00728.2013","article-title":"Temporal hemodynamic and histological progression in Sugen5416\/hypoxia\/normoxia-exposed pulmonary arterial hypertensive rats","volume":"306","author":"Toba","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/j.2040-4603.2012.tb00402.x","article-title":"Structure and composition of pulmonary arteries, capillaries and Veins","volume":"2","author":"Townsley","year":"2013","journal-title":"Comp. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib47","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib48","doi-asserted-by":"crossref","first-page":"L401","DOI":"10.1152\/ajplung.00114.2010","article-title":"Validation of high resolution echocardiography and magnetic resonance imaging vs. high fidelity catheterization in experimental pulmonary hypertension","volume":"299","author":"Urboniene","year":"2010","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejphar.2021.174484_bib49","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/678508","article-title":"The Sugen 5416\/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up","volume":"4","author":"Vitali","year":"2014","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2021.174484_bib50","article-title":"Progressive right ventricular functional and structural changes in a mouse model of pulmonary arterial hypertension","volume":"1","author":"Wang","year":"2013","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejphar.2021.174484_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174484_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10408449309104076","article-title":"Toxicologic testing of inhaled pharmaceutical aerosols","volume":"23","author":"Wolff","year":"1993","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ejphar.2021.174484_bib53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCRESAHA.109.209940","article-title":"Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in Vitro and in Vivo","volume":"107","author":"Yang","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174484_bib54","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1378\/chest.15-1029","article-title":"Prostanoids in asthma and COPD, actions, dysregulation, and therapeutic opportunities","volume":"148","author":"Zaslona","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2021.174484_bib55","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.113.003139","article-title":"Endothelial-like progenitor cells engineered to produce prostacyclin rescue monocrotaline-induced pulmonary arterial hypertension and provide right ventricle benefits","volume":"128","author":"Zhou","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174484_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019841987","article-title":"Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension","volume":"9","author":"Zhu","year":"2019","journal-title":"Pulm. Circ."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:58:47Z","timestamp":1757977127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":56,"alternative-id":["S0014299921006385"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174484","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174484"}}